APA (7th ed.) Citation

Fong, C., Iyer, S., Potts, L., Peckitt, C., Cromarty, S., Saffery, C., . . . Cunningham, D. (2022). 1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. Annals of Oncology, 33, S1110. https://doi.org/10.1016/j.annonc.2022.07.1344

Chicago Style (17th ed.) Citation

Fong, C.Y.K, et al. "1226P Predicting Benefit from Maintenance Durvalumab After First-line Chemotherapy (1L CTx) in Oesophagogastric Adenocarcinoma (OGA) Using a Novel Tumour Microenvironment (TME) RNA-based Assay." Annals of Oncology 33 (2022): S1110. https://doi.org/10.1016/j.annonc.2022.07.1344.

MLA (9th ed.) Citation

Fong, C.Y.K, et al. "1226P Predicting Benefit from Maintenance Durvalumab After First-line Chemotherapy (1L CTx) in Oesophagogastric Adenocarcinoma (OGA) Using a Novel Tumour Microenvironment (TME) RNA-based Assay." Annals of Oncology, vol. 33, 2022, p. S1110, https://doi.org/10.1016/j.annonc.2022.07.1344.